Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Entos Pharmaceuticals is set to develop a DNA vaccine for Covid-19 coronavirus infection using its Fusogenix drug delivery platform.
A DNA vaccine directly delivers a plasmid encoding the antigen(s) to generate an immune response. It involves the generation of the target antigen in the patient’s own cells.
The Fusogenix platform is a proteo-lipid vehicle (PLV) designed to leverage a fusion mechanism to introduce its genetic payload directly inside cells.
Entos created different formulations to deliver various genetic therapies, including plasmid DNA. Plasmid DNA in a vaccine is expected to enable the design of an optimised payload that encodes several